Neutralising anti‐drug antibodies in Fabry disease can inhibit endothelial enzyme uptake and activity

Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human Primates

(2019) Xuling Zhu et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Mutation-specific Fabry disease patient-derived cell model to evaluate the amenability to chaperone therapy

(2019) Malte Lenders et al.   JOURNAL OF MEDICAL GENETICS

Characterization of drug-neutralizing antibodies in patients with Fabry disease during infusion

(2018) Malte Lenders et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study

(2018) Maarten Arends et al.   JOURNAL OF MEDICAL GENETICS

Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease

(2018) Malte Lenders et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY

(2018) Wladimir Mauhin et al.   Orphanet Journal of Rare Diseases

Dose-Dependent Effect of Enzyme Replacement Therapy on Neutralizing Antidrug Antibody Titers and Clinical Outcome in Patients with Fabry Disease

(2018) Malte Lenders et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Antibodies against recombinant alpha-galactosidase A in Fabry disease: Subclass analysis and impact on response to treatment

(2018) S.J. van der Veen et al.   MOLECULAR GENETICS AND METABOLISM

Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease

(2015) M. Lenders et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Pathophysiological advances in membranous nephropathy: time for a shift in patient's care

(2015) Pierre Ronco et al.   LANCET

Allo-Immune Membranous Nephropathy and Recombinant Aryl Sulfatase Replacement Therapy: A Need for Tolerance Induction Therapy

(2013) H. Debiec et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Long-Term Effect of Antibodies against Infused Alpha-Galactosidase A in Fabry Disease on Plasma and Urinary (lyso)Gb3 Reduction and Treatment Outcome

(2012) Saskia M. Rombach et al.   PLoS One

Fabry's disease

(2008) Yuri A Zarate et al.   LANCET

Treatment of Fabry disease with different dosing regimens of agalsidase: Effects on antibody formation and GL-3

(2008) Anouk C. Vedder et al.   MOLECULAR GENETICS AND METABOLISM

A retrospective analysis of the potential impact of IgG antibodies to agalsidase β on efficacy during enzyme replacement therapy for Fabry disease

(2008) Bernard Bénichou et al.   MOLECULAR GENETICS AND METABOLISM